| NRO | XLRE | NRO / XLRE | |
| Gain YTD | -5.098 | 2.727 | -187% |
| Net Assets | 202M | 7.46B | 3% |
| Total Expense Ratio | 2.06 | 0.08 | 2,575% |
| Turnover | 18.00 | 5.00 | 360% |
| Yield | 11.48 | 3.40 | 338% |
| Fund Existence | 22 years | 10 years | - |
| NRO | XLRE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| Advances ODDS (%) | 15 days ago 82% | 20 days ago 87% |
| Declines ODDS (%) | 3 days ago 83% | 7 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 81% | N/A |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| USOI | 49.87 | 0.61 | +1.23% |
| UBS ETRACS Crude Oil Shares Cov Cll ETN | |||
| THNR | 25.22 | 0.23 | +0.94% |
| Amplify Weight Loss Drug & Treatment ETF | |||
| LCLG | 60.58 | N/A | N/A |
| Logan Capital Broad Innovative Gr ETF | |||
| LAPR | 25.16 | N/A | N/A |
| Innovator Premium Inc 15 Bffr ETF - Aprl | |||
| IPAC | 72.65 | -1.22 | -1.65% |
| iShares Core MSCI Pacific ETF | |||
A.I.dvisor tells us that NRO and SPG have been poorly correlated (+18% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NRO and SPG's prices will move in lockstep.